Paradigm announces a partnership with Japan’s leading health information prover, Fujitsu. With the support of national Japanese leaders, we’re honored to partner with Fujitsu to create a more robust infrastructure and bring more trials to providers and patients in Japan. Below are CEO Kent Thoelke’s remarks from our press conference in Japan on August 26, 2024:
Thank you Tatsuki for that introduction and for sharing this critical vision for a new patient future that Fujitsu is creating. When I founded Paradigm it was with a similar vision to what Fujitsu is solving with Uvance Healthy Living - that every single patient should have access to the best possible care for their disease inclusive of a clinical trial as a care option. No patient should lack the access to these treatment options as a result of where they live, their ethnic background, their socioeconomic status, or the physician or medical institution where they are being treated. This includes the disparities created by the drug loss problem created by global clinical trial development strategies.
What we have created at Paradigm with our platform is a new future for clinical research care that leverages all of the latest advancements in digital technology, large language models and analytics to maximize the efficiency in clinical trials. While the biopharma industry has made significant advances in bringing life saving and life changing drugs to market over the last several decades, the clinical trial process and methodology has failed to keep pace with technological advances to leverage access to medical data at scale, to design and execute clinical trials. This has resulted in far too few patients globally and specifically in Japan having access to clinical trials, unacceptably long timelines to bring new drugs to market, and as a result drug development costs that are no longer sustainable for the biopharma industry. Our model and our partnership with Fujitsu will allow us to solve these problems with the result being more efficient clinical trials that are widely available to the patients in Japan that need them while lowering costs and timelines to bring new drugs to market.
For the biopharma industry, one of the major challenges today is that clinical trials recruit patients too slowly, resulting in long delays in getting data to support bringing new drugs to market and driving research and development costs up to a level that is now limiting their ability to expand their drug pipelines to bring even more new drugs to market. By creating a data driven model that leverages the most current technology and embedding this platform within the healthcare delivery model - clinical trials become accessible to virtually all potential patients. As Paradigm has demonstrated in the United States, this scaled access model can significantly increase patient clinical trial recruitment, biopharma can potentially decrease their time to market by years resulting in a more robust financial model allowing them to put more novel drugs into development.
For physicians and medical institutions - this new model allows them the ability to ensure that every patient has access to the best possible treatment options - including clinical trials as a care option. It ensures that patients being treated in Japan by world class physicians have the same access to the latest and most innovative drugs and treatment options that are available outside of Japan.
One of the challenges that physicians and medical institutions have today is that clinical trials are time consuming to participate in and require a significant amount of manual labor investment by physicians, nurses and data teams to conduct the trials, care for the patient and collect the necessary data to ensure the drugs are safe and efficacious. Fujitsu and Paradigm intend to solve this by deploying the Paradigm Platform to hospitals in Japan, leveraging data integrations with Fujitsu's Healthy Living Platform, to minimize the labor needed to conduct these trials by maximizing the process efficiency of matching patients to clinical trials and collecting their data in support of the trials. This will allow Japanese physicians and medical institutions to participate in many more clinical trials without the need for increasing their internal labor and costs.
Paradigm is honored to be partnering with Fujitsu to deploy our clinical trial platform to hospitals throughout Japan to realize our shared vision of resolving drug loss in Japan. We are excited that this partnership is much more than simply deploying our platform – we are collaborating together to develop new solutions that enhance the health and wellbeing of patients in Japan.
My expectation is that this industry leading partnership will reduce or eliminate drug loss in Japan. By creating one of the most efficient clinical trial models in the world, Japan should be included in all global clinical trials while simultaneously ensuring Japanese patients have the same access at the same time to innovative drug therapies that can positively impact their lives.
About Paradigm
Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.
